UniProtKB/Swiss-Prot P15812 : Variant p.Ser149Asn
T-cell surface glycoprotein CD1e, membrane-associated
Gene: CD1E
Feedback ?
Variant information
Variant position:
149
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Serine (S) to Asparagine (N) at position 149 (S149N, p.Ser149Asn).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and polar (S) to medium size and polar (N)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
Six alleles of CD1E are known. CD1E*01 has His-102/Gln-106/Ser-149/Arg-164/Leu-194, CD1E*02 has His-102/Arg-106/Ser-149/Arg-164/Leu-194, CD1E*03 (9L) has His-102/Gln-106/Ser-149/Trp-164/Leu-194, CD1E*04 (15L) has His-102/Gln-106/Ser-149/Arg-164/Pro-194, CD1E*05 has Arg-102/Arg-106/Ser-149/Arg-164/Leu-194 and CD1E*06 has His-102/Arg-106/Asn-149/Arg-164/Leu-194 (PubMed:11019917 , PubMed:12144626 , PubMed:18325888 ). The sequence shown is that of allele CD1E*01.
Additional information on the polymorphism described.
Variant description:
In allele CD1E*05.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
149
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
388
The length of the canonical sequence.
Location on the sequence:
CRMNAPQIFLNMAYQGSDFL
S FQGISWEPSPGAGIRAQNIC
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
20 – 388
T-cell surface glycoprotein CD1e, membrane-associated
Chain
32 – 388
T-cell surface glycoprotein CD1e, soluble
Alternative sequence
20 – 208
Missing. In isoform 8, isoform 9, isoform 10, isoform 11 and isoform 12.
Alternative sequence
119 – 209
YPFEIQILAGCRMNAPQIFLNMAYQGSDFLSFQGISWEPSPGAGIRAQNICKVLNRYLDIKEILQSLLGHTCPRFLAGLMEAGESELKRKV -> L. In isoform 5, isoform 6 and isoform 7.
Literature citations
Two novel CD1 E alleles identified in black African individuals.
Tamouza R.; Sghiri R.; Ramasawmy R.; Neonato M.G.; Mombo L.E.; Poirier J.C.; Schaeffer V.; Fortier C.; Labie D.; Girot R.; Toubert A.; Krishnamoorthy R.; Charron D.;
Tissue Antigens 59:417-420(2002)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 31-208 (ALLELES CD1E*05 AND CD1E*06); POLYMORPHISM; VARIANTS ARG-102; ARG-106; ASN-149 AND TRP-164;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.